Indication
Lymphatic Diseases
10 clinical trials
16 products
3 drugs
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell LymphomaStatus: Withdrawn, Estimated PCD: 2026-11-01
Product
PlaceboProduct
ZilovertamabProduct
IbrutinibProduct
Sepantronium BromideClinical trial
A Phase 2, Multicenter, Open Label Dose-ranging Study of Sepantronium Bromide in Patients With Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma (HGBCL)Status: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient SettingStatus: Completed, Estimated PCD: 2023-09-22
Product
Lisocabtagene maraleucelClinical trial
Phase I Study of the Administration of T Lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and Cutaneous T-Cell LymphomaStatus: Recruiting, Estimated PCD: 2026-09-30
Product
ATLCAR.CD30.CCR4Product
ALTCAR.CD30Clinical trial
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood UnitsStatus: Recruiting, Estimated PCD: 2025-12-01
Product
Umbilical Cord BloodProduct
BendamustineDrug
fludarabineClinical trial
Brentuximab Vedotin With Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Adult T-Cell Leukemia/Lymphoma: A Pilot Study of the Rare Lymphoma Working GroupStatus: Active (not recruiting), Estimated PCD: 2023-12-15
Product
Brentuximab VedotinProduct
CHEPClinical trial
A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell LymphomaStatus: Recruiting, Estimated PCD: 2027-03-22
Product
iC9-CAR19 T cellsProduct
FludarabineProduct
AP1903Drug
cyclophosphamideClinical trial
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)Status: Active (not recruiting), Estimated PCD: 2021-01-15
Product
ATLCAR.CD30Clinical trial
Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2025-08-26
Clinical trial
Octreotide Improves Human Lymphatic Fluid Transport a Translational TrialStatus: Completed, Estimated PCD: 2021-03-26
Product
OctreotideDrug
Varlilumab